FGEN שיעור רווח גולמי FibroGen Corp

FibroGen, Inc. (FGEN) utilizes a patent economy model, scaling profits through global licenses. The development of treatments for fibrosis and anemia is conducted in laboratories across the US and China. Historical gross margins demonstrate production efficiency, with the current figure standing at 153.90. Proven contract manufacturing plants ensure supply stability, eliminating drug shortages in the market.
פילוחים אנליטיים ודוחות נתונים של חברת FibroGen (FGEN)

Finding a balance between operational risks and return on capital at FibroGen, Inc. (FGEN) requires an analysis of its dependence on external CMO manufacturers. The aggregate gross margin reflects the profit share after deducting the cost of goods sold, demonstrating how effectively the R&D center converts intellectual property into revenue, which allows investors to assess the business model's resilience to outsourcing costs and determine the fairness of the market valuation.